ACTUATE THERAPEUTICS, INC. (ACTU) Stock Research
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing sarcoma, as well as neuroblastoma and pediatric leukemias. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. Actuate Therapeutics, Inc. was incorporated in 2015 and is headquartered in Fort Worth, Texas.
Latest price: 0.3829 · Sector: Healthcare
Recent Insider Transactions
| Insider | Type | Date | Value |
|---|---|---|---|
| SCHMITT DANIEL M | buy | 2026-10-28 | 49999.62 |
| THOMSON TODD S | sell | 2026-01-05 | 1624000 |
| Kreis Leslie W. | buy | 2025-06-27 | 499996 |
| Fletcher Aaron G.L. | buy | 2025-06-27 | 499996 |
| Bios Equity COF, LP | buy | 2025-06-27 | 499996 |
| Bios Equity COF, LP | sell | 2024-08-14 | 18592 |
| Bios Equity COF, LP | sell | 2024-08-14 | 138888 |
| Fletcher Aaron G.L. | sell | 2024-08-14 | 18592 |
| Fletcher Aaron G.L. | sell | 2024-08-14 | 138888 |
| Fletcher Aaron G.L. | sell | 2024-08-14 | 42512 |